Introduction {#s1}
============

Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin's lymphoma (NHL), accounting for about 25% of all adult NHLs worldwide \[[@R01]\]. DLBCL is a heterogeneous group of tumors including large transformed B cells with prominent nucleoli and basophilic cytoplasm, a diffuse growth pattern and 30-90% Ki67 positive cells \[[@R02]\]. DLBCL tumor cells express pan B cell antigens (cluster of differentiation (CD)19, CD20, CD22, CD79a, PAX5), but there is no single diagnostic cytogenetic change \[[@R02]\]. T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is an extremely rare morphologic subtype of DLBCL, accounting for only 1-3% of total cases \[[@R03]-[@R06]\]. The World Health Organization (WHO) defines THRLBCL as the presence of less than 10% of large malignant CD20-expressing B cells scattered in a background of predominant reactive T cells and histiocytes \[[@R01]\]. At presentation THRLBCL is often seen in middle-aged men with an advanced stage (III or IV) frequently involving the spleen, liver and bone marrow \[[@R07]\]. Given this, THRLBCL is considered an aggressive lymphoma with a poor prognosis. Hypercalcemia has been reported in up to 15% of NHL patients during their clinical course but is uncommon at diagnosis \[[@R08]\]. Hypercalcemia has been described as a rare presenting symptom of patients with DLBCL in several case reports \[[@R9]-[@R11]\]. Presently, there is no published case report in the literature of THRLBCL presenting as severe hypercalcemia. In this paper, we describe the first case.

Case Report {#s2}
===========

A 69-year-old male with a history of hypothyroidism and hypertension presented to the Emergency Department of our hospital with complaints of nausea, vomiting, and generalized weakness with left-sided discomfort for the last 2 weeks. The patient also reported unintentional 80-pound weight loss over the last 1 year. He denied fevers, chills or night sweats. Upon initial physical examination the patient was cachectic with dry mucous membranes. The remainder of the exam was within normal limits. His vital signs were as follows: blood pressure: 136/72 mm Hg; heart rate: 90 beats per minute; respiratory rate: 18/min; body temperature: 36.6 °C; oxygen saturation: 98% at room air.

The results of a complete metabolic panel ([Table 1](#T1){ref-type="table"}) showed serum calcium level elevated at 16.1 mg/dL. The patient was admitted to the intensive care unit for severe hypercalcemia, for which he received aggressive intravenous fluid resuscitation with 2 L normal saline followed by maintenance fluids at 150 mL/h (with goal urine output 100 mL/h), as well as intravenous calcitonin for goal decrease in serum calcium of 2 mg/dL/24 h. Several hours after administration of calcitonin, serum calcium level decreased to 13.5 mg/dL. In addition, serum blood urea nitrogen and creatinine were initially elevated at 67 mg/dL and 3.25 mg/dL, respectively. Thyroid function test was normal. Furthermore, serum assay of intact parathyroid hormone (iPTH) was 6.8 pg/mL (range: 15 - 65 pg/mL), serum 25-hydroxyvitamin D (25(OH)D) level was 168 pg/mL (range: 19.9 - 79.3 pg/mL), and serum PTH-related peptide (PTHrP) was elevated at 3.7 pmol/L (range: 0.0 - 2.3 pmol/L) ([Table 1](#T1){ref-type="table"}). A workup for anemia was simultaneously carried out ([Table 1](#T1){ref-type="table"}). Iron panel was consistent with anemia due to chronic disease. The peripheral blood smear was unremarkable. The level of β2-microglobulin was elevated to 9.8 mg/L (range: 1.1 - 2.4 mg/L). Due to the combination of severe hypercalcemia, renal failure and anemia, serum and urine electrophoreses were performed to rule out multiple myeloma. Both tests were negative. Computed tomography (CT) chest/abdomen/pelvis and CT head were unremarkable. Skeletal survey was within normal limits. A bone marrow biopsy at the left posterior superior iliac spine was then performed to exclude any hematologic malignancy. The bone marrow smear revealed large mononuclear cells with prominent nucleoli and occasional Reed-Sternberg cells, consistent with THRLBCL ([Fig. 1](#F1){ref-type="fig"}). The atypical cells exhibited the following immunophenotype: cluster of differentiation (CD)30+, CD20+, PAX5+, organic cation transporter 2 (Oct2)+, BOB1+, CD79a+, BCL6+, BCL2+, C-MYC+, MIB1+, and MUM1+. CD3 marks associated T-cell infiltrate. Special staining with CD71, CD61 and myeloperoxidase (MPO) was utilized. Flow cytometry and cytogenetics were unremarkable. This pathology was reviewed in consultation with the pathologist from the National Institute of Health, who confirmed the morphological and immunohistochemical characterization of THRLBCL.

###### Summary of Laboratory Results

                                         Result   Reference range
  -------------------------------------- -------- -----------------
  Complete metabolic panel                        
    Sodium (mmol/L)                      138      136 - 145
    Potassium (mmol/L)                   4.1      3.5 - 5.2
    Chloride (mmol/L)                    96       96 - 110
    Bicarbonate (mmol/L)                 29       24 - 31
    Calcium (mg/dL)                      16.1     8.5 - 10.5
    Magnesium (mg/dL)                    1.9      1.3 - 2.5
    Phosphorous (mg/dL)                  5.8      2.5 - 4.6
    BUN (mg/dL)                          67       5.0 - 25
    Creatinine (mg/dL)                   3.25     0.61 - 1.24
    eGFR (mL/min)                        19       \> 60
    Intact parathyroid hormone (pg/mL)   6.8      15 - 65
    PTH-related peptide(pmol/L)          3.7      0.0 - 2.3
    25-hydroxyvitamin D (pg/mL)          168      19.9 - 79.3
    β2-microglobulin (mg/L)              9.8      1.1 - 2.4
  Complete blood count                            
    WBC (×10^3^/µL)                      4.3      4.5 - 11.0
    Hemoglobin (g/dL)                    11.4     12.0 - 17.5
    Hematocrit (%)                       34.0     36.0-53.0
    MCV (fL)                             84.0     80.0 - 100
    MCH (pg)                             28.1     25.0 - 35.0
    Platelet count (×10^3^/µL)           206      140 - 450
  Iron panel                                      
    Iron (µg/dL)                         78       45 - 180
    Iron binding (µg/dL)                 265      260 - 480
    Ferritin (ng/mL)                     681.5    24 - 336
    Transferrin ((mg/dL))                189      215 - 365
    Transferrin % saturation (%)         29.5     15-50

![Bone marrow smears demonstrating T-cell/histiocyte rich large B-cell lymphoma. (a) Low-power view. (b) High-power view. (c) PAX8 immunostain. (d) CD3 immunostain. CD: cluster of differentiation. BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate; WBC: white blood cell; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin.](wjon-10-06-231-g001){#F1}

Throughout his hospital stay the patient remained on intravenous maintenance normal saline at 150 mL/h, and his creatinine improved to 1.68 prior to discharge. In addition, patient received intravenous calcitonin, one dose of intravenous pamidronate and furosemide, and zoledronic acid for symptomatic hypercalcemia which significantly improved his calcium to 10.9 at its lowest. The patient was discharged in a stable condition with close follow-up. A following outpatient positron emission tomography/computed tomography (PET/CT) scan showed extensive skeletal metastatic disease with fluorodeoxyglucose (FDG) uptake involving all bones, 5-cm mediastinal mass and diffuse splenic disease with 3.98-cm mass, an atypical presentation of lymphoma ([Fig. 2](#F2){ref-type="fig"}). The patient's international prognostic index (IPI) was 4 which indicated high risk for shorter overall survival, specifically 26% chance 5-year survival according to the International Peripheral T-cell Lymphoma Project \[[@R12]\]. The patient consistently followed up as an outpatient with medical oncology and completed four cycles of hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone (hyper-CVAD) chemotherapy without complications. After 8 months of initial presentation, repeat PET/CT showed complete remission of his lymphoma with improvement of labs. The patient remained in complete remission for over 1 year since the end of treatment. At his most recent office visit, patient was asymptomatic with positive weight gain and normal appetite.

![Torso positron emission tomography/computed tomography scan demonstrates diffuse fluorodeoxyglucose (FDG) uptake and a 3.98-cm splenic mass.](wjon-10-06-231-g002){#F2}

Discussion {#s3}
==========

This case highlights the importance of pursuing a thorough workup for rare underlying causes of hypercalcemia, especially in patients who show elevated PTHrP. Hypercalcemia is commonly seen in 20-30% of cancer cases, occurring in both solid and hematologic malignancies \[[@R13]\]. The most common cancers in the USA that are associated with hypercalcemia are multiple myeloma, breast, renal and lung cancers \[[@R14]\]. Malignancy is usually clinically evident by the time it causes hypercalcemia. Symptoms can include lethargy, weakness dehydration, nausea, vomiting and constipation. Only 15% of NHL patients will develop hypercalcemia during their overall clinical course \[[@R08]\]. But rarely does hypercalcemia manifest at the time of diagnosis. Hypercalcemia of malignancy is often associated with poor prognosis, and therefore, it is important to understand the mechanisms behind hypercalcemia associated with cancer.

Three major mechanisms by which hypercalcemia of malignancy can occur have been described in the literature: tumor secretion of PTHrP, osteolytic metastases with local release of cytokines and osteoclast activating factors, and tumor production of calcitriol (1, 25-dihydroxyvitamin D) \[[@R13], [@R15], [@R16]\]. The most common mechanism of hypercalcemia (accounting up to 80%) in patients with NHL and non-metastatic tumors is secretion of PTHrP, known as humoral hypercalcemia of malignancy (HHM) \[[@R17]-[@R19]\]. Malignant tissues such as squamous-cell carcinomas (lung, head and neck), breast cancer, chronic myeloid leukemia and NHL produce excess PTHrP, resulting in HHM. PTHrP has close homology with PTH and binds to the same PTH-1 receptors, thus activating similar pathways. PTHrP circulates throughout the body and increases distal tubular calcium reabsorption and bone resorption, resulting in large flux of calcium storage release into the circulation \[[@R19], [@R20]\]. Conversely, osteolytic metastases account for merely 20% of cases of hypercalcemia with malignancy \[[@R21]\]. In solid tumors that are metastatic to bone, tumor cells produce factors that stimulate osteoclast production. This in turn induces local osteolysis, increased skeletal resorption and hypercalcemia. Another common mechanism by which hypercalcemia of malignancy can occur is increased production of calcitriol by certain lymphomas. Active secretion stimulates both osteoclastic bone resorption and intestinal calcium absorption, leading to hypercalcemia \[[@R13]\].

Upon evaluating the cause of severe unexplained hypercalcemia, the first step is to measure the iPTH value to screen for HHM. A low serum iPTH suggests the possibility of malignancy and warrants measurement of PTHrP and vitamin D \[[@R22]\]. In contrast, an elevated iPTH indicates primary hyperparathyroidism. Additional laboratory data such as serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP) and thyrotropin (TSH) can aid in identifying other possible sources for hypercalcemia. PTHrP elevation is often seen in HHM but can also be due to other benign conditions such as systemic lupus erythematosus \[[@R23]\]. Therefore, it is important to pay careful attention to laboratory interpretation in patients who present with severe hypercalcemia of unclear etiology.

There are several case reports that describe lymphomas presenting as severe, unexplained hypercalcemia \[[@R9]-[@R11], [@R24], [@R25]\]. Hong et al reported a case of DLBCL in a 72-year-old male who presented with worsening confusion and dehydration and who, like our case, was found to have severe hypercalcemia along with high plasma concentration of PTHrP. Subsequent imaging revealed a large hepatosplenic mass. Pathology confirmed diagnosis of DLBCL \[[@R10]\]. Tumor cell production of PTHrP likely explained the pathogenesis of hypercalcemia. However, our case is unique as this patient presented with severe hypercalcemia as the initial manifestation of THRLBCL, an extremely rare subtype of DLBCL. Ha et al also described a 68-year-old male who presented with lethargy, weight loss, severe hypercalcemia and elevated PTHrP. PET/CT imaging likewise revealed diffuse FDG uptake in the bones and spleen. Up until now, however, there are no published cases in the literature that describe hypercalcemia as a rare manifestation of THRLBCL \[[@R9]\].

Given the rarity, aggression and acuity of THRLBCL as a distinct clinicopathologic entity, successful treatment outcomes have not yet been well reported as uncertainty remains regarding the best therapeutic approach. Achten et al reports the IPI as a significant correlate to response to treatment and survival based on multivariate analysis. In this study on 40 THRLBCL patients, the IPI was ≥ 2 in 77% of the patients \[[@R26]\]. Despite treatment with combination chemotherapy, complete remission was attained in only 40% of patients with an overall survival rate of 50% at 3 years. Moreover, several retrospective studies that compared overall and event-free survival rates between DLBCL and THRLBCL patients treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy showed that THRLBCL has a worse prognosis, thus requiring more aggressive therapy \[[@R26], [@R27]\]. Although THRLBCL confers a poor prognosis, our patient with an IPI score of 4 achieved complete remission by treatment with four cycles of hyper-CVAD. Nevertheless, insights into the pathogenesis of this disease should be explored further to achieve targeted therapies that can offer a more favorable treatment response.

Conclusions {#s3a}
-----------

In conclusion, we present a unique presentation of an extremely rare clinicopathologic entity. A literature search revealed no previously reported cases of THRLBCL manifesting as severe hypercalcemia. We thus suggest that THRLBCL should be included in the differential diagnosis and active workup in patients with severe unexplained hypercalcemia in appropriate clinical scenario, as this aggressive malignancy with poor prognosis requires prompt recognition and treatment.
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